InspireMD Inc. (NSPR) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for NSPR, including 3 earnings updates, 3 SEC filings and 2 offerings. The most recent was published Nov 13, 2026.
Financial highlights
Full financials- Revenue, TTM
- $10.84M
- Revenue growth
- +53.4%
- Net income, TTM
- -$52.48M
- Net margin
- -484.1%
- Free cash flow, TTM
- -$42.46M
- Cash
- $15.15M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks28+125%
2026-05-172026-11-08
Mix1590d
- SEC Filings5(33%)
- Insider3(20%)
- Earnings3(20%)
- Other2(13%)
- Offering2(13%)
Activity · 52 weeks7852 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRInspireMD Announces Pricing of $37.5 Million Public OfferingMIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 50,350,000 shares of its common stock, and (iii) accompanying common warrants to purchase 43,269,231 shares of its common stock (or pre-funded warrants in lieu thereof). All securities in the offering are being offered by InspireMD. In addition, the Company granted the underwriters a 30-day option
- SECSEC Form 424B5 filed by InspireMD Inc.424B5 - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD Announces Proposed Public OfferingMIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it has commenced a proposed public offering of (i) shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock, and (iii) accompanying common warrants to purchase shares of its common stock or pre-funded warrants in lieu thereof to purchase shares of its common stock. All securities in the proposed offering are being offered by InspireMD. In addition, the Company intends to grant the underwriters a 30-day opti
- PRInspireMD Reports Third Quarter 2026 Financial Results- Received FDA approval of CGuard® Prime for Transcarotid Arterial Revascularization (TCAR) procedures, expected to approximately double the U.S. addressable market - - Company to host investor conference call today, November 12th, at 4:30pm ET - MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and nine months ended September 30, 2026. Recent Business Highlights: Received U.S. Food and Drug Administration ("FDA") approval of the CGuard® Prime TransCarotid Stent System ("CGuard Prime for TCAR
- PRInspireMD Announces FDA Approval of the CGuard® Prime TransCarotid Stent System for Transcarotid Artery Revascularization (TCAR) Procedures- Approval doubles the CGuard Prime platform’s total addressable market in the U.S. with additional access to over 35,000 TCAR procedures annually – - Approval supported by CGUARDIANS II pivotal trial data, which demonstrated 100% acute device success and zero death, stroke, myocardial infarction or stent thrombosis reported at 30 days - MIAMI, Nov. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the U.S. Food and Drug Administration ("FDA") has approved the Company’s Premarket Approval ("PMA") Supplement for the CGuard® Prime TransCarotid
- PRInspireMD Announces Updated Timing for Third Quarter 2026 Financial ResultsMIAMI, Nov. 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it has rescheduled its third quarter 2026 financial results conference call and webcast to 4:30 p.m. Eastern Time, after the close of U.S. financial markets on Thursday, November 12, 2026, from its previously announced time of 8:30 a.m. Eastern Time. The revised timing will allow management to provide investors with a more comprehensive update on the Company’s recent developments and business activities in conjunction with its third quarter financial results. Parties interested in participating by phone should regis
- PRInspireMD to Announce Third Quarter 2026 Financial ResultsMIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter financial results on Thursday, November 12, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number along with a personal pin. A live audio web
- INSIDERSEC Form 4 filed by Director Roubin Gary S4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERSEC Form 4 filed by Director Berman Michael4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERSEC Form 4 filed by Director Stuka Paul4 - InspireMD, Inc. (0001433607) (Issuer)
- SECInspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment ConferenceMIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14th at 2:30 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the investors page of InspireMD’s corporate website at https://investors.inspiremd.com. To request a meeting or for more details about the conferences, please reach out to your institutional contact. About InspireMD, Inc.InspireMD seeks to utilize its proprietary Micr
- SECInspireMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form 10-Q filed by InspireMD Inc.10-Q - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD to Announce Second Quarter 2026 Financial ResultsMIAMI, Aug. 10, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced it will issue its press release for its second quarter financial results on Monday August 17, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in details will be provided in an auto-generated e-mail containing a link to the conference phone number a
- PRInspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and MarketingMIAMI, July 30, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of accomplished commercial leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing, reporting to CEO Marvin Slosman. Ms. Kennedy brings more than 30 years of medical device sales leadership experience, including significant expertise in carotid intervention and carotid stenting. Having previously led regional sales efforts supporting the U.S. launch of CGuard Prime, she returns to InspireMD with deep relationships across the vascular, neurovascular and c
- SECInspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR ProceduresMIAMI, June 11, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced 30-day outcomes from the CGUARDIANS II clinical trial of the CGuard Prime 80cm implant for use in transcarotid artery revascularization (TCAR) procedures. InspireMD anticipates potential approval of the CGuard Prime 80 cm stent implant in the second half of this year. Key 30-day outcomes observed in the CGUARDIANS II trial include: Acute device success was achieved in 100% (50/50) of patients;No deaths, strokes, or myocardial infarctions were reported within 30 days;No stent thrombosis was
- PRInspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR ProceduresMIAMI, June 08, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that the first patient has been enrolled in the CGUARDIANS III pivotal study of its SwitchGuard neuro protection system ("NPS"), for use with its CGuard Prime 80 cm stent platform, in transcarotid artery revascularization ("TCAR") procedures. The patient was enrolled by Dr. Patrick Muck at Good Samaritan Hospital, part of the TriHealth System in Cincinnati, Ohio. Dr. Muck and Dr. Patrick Geraghty, professor of surgery and radiology, section of vascular surgery at Washington University School
- SECInspireMD Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
NSPR FAQ
10 questionsWhat does InspireMD Inc. do?
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that...What is the latest news on NSPR?
In the last 30 days Quantisnow tracked 9 wire items for NSPR: 3 earnings updates, 3 SEC filings, 2 offerings and 1 press release or news item. The most recent was published on November 13, 2026.What is NSPR revenue?
InspireMD Inc. (NSPR) reported $10.84M of revenue for the twelve months ended Jun 30, 2026. That is up 53.4% from the year before. Revenue for fiscal 2025 was $8.98M.Is NSPR profitable?
No. InspireMD Inc. reported a net loss of $52.48M for the twelve months ended Jun 30, 2026.How much cash and debt does NSPR have?
InspireMD Inc. reported $15.15M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does NSPR stock trade?
InspireMD Inc. (NSPR) is listed on NASDAQ.What sector and industry is NSPR in?
InspireMD Inc. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about NSPR?
InspireMD Inc. has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $6.00 price target on 2026-02-02. Recent price targets cluster around $6.00.What companies are similar to NSPR?
Notable peers in the same industry include ABT (Abbott Laboratories), SYK (Stryker Corporation), EW (Edwards Lifesciences Corporation), MDT (Medtronic plc.), BSX (Boston Scientific Corporation). Compare NSPR side-by-side with any of them on Quantisnow.How can I track NSPR on Quantisnow?
Quantisnow aggregates InspireMD Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NSPR to receive live email and push alerts on every new disclosure.